oesophageal cancer Archives -

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

Phil Taylor BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab 0 Comment

Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

https://pharmaphorum.com/oncology/novartis-eyes-earlier-use-of-pd-1-drug-in-oesophageal-cancer/

News/ News/ Oncology

BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA

Phil Taylor Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo, regulatory approval 0 Comment

The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously-untreated advanced

BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA

https://pharmaphorum.com/news/bms-opdivo-gets-late-stage-oesophageal-cancer-nod-from-fda/

News/ News/ Oncology

EMA starts review of Novartis’ latecomer PD-1 drug tislelizumab

Phil Taylor alpelisib, immuno-oncology, Non-small cell lung cancer, Novartis, oesophageal cancer, Oncology, regulatory approval, tislelizumab 0 Comment

The EU regulator has started a review of Novartis’ PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene –

EMA starts review of Novartis’ latecomer PD-1 drug tislelizumab

https://pharmaphorum.com/news/ema-starts-review-of-novartis-latecomer-pd-1-drug-tislelizumab/

News/ News/ Oncology

BMS strikes back against Merck in EU oesophageal cancer market

Phil Taylor Bristol-Myers Squibb, gastric cancer, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo 0 Comment

Merck & Co’s Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment

BMS strikes back against Merck in EU oesophageal cancer market

https://pharmaphorum.com/news/bms-strikes-back-against-merck-in-eu-oesophageal-cancer-market/

Market Access/ News/ News

Keytruda backed by NICE for late-stage oesophageal cancer

Phil Taylor HEOR, immuno-oncology, Keytruda, Merck & Co, NHS, NICE, oesophageal cancer, Oncology 0 Comment

MSD’s Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making

Keytruda backed by NICE for late-stage oesophageal cancer

https://pharmaphorum.com/news/keytruda-backed-by-nice-for-late-stage-oesophageal-cancer/

News/ News/ Oncology/ Top stories

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

Phil Taylor BeiGene, fda, immuno-oncology, Novartis, oesophageal cancer, Oncology 0 Comment

Novartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

https://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/

News/ News/ Oncology

BMS claims first EU okay for adjuvant oesophageal cancer immunotherapy

Phil Taylor adjuvant, Bristol-Myers Squibb, EU, immuno-oncology, oesophageal cancer, Oncology, Opdivo 0 Comment

Bristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy

BMS claims first EU okay for adjuvant oesophageal cancer immunotherapy

https://pharmaphorum.com/news/bms-claims-eu-okay-for-opdivo-in-adjuvant-oesophageal-cancer/

News/ News/ Sales and Marketing

Keytruda beats Opdivo to first-line oesophageal cancer OK in Europe

Phil Taylor Bristol-Myers Squibb, EU, Keytruda, Merck & Co, oesophageal cancer, Opdivo, regulatory approval 0 Comment

Merck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer

Keytruda beats Opdivo to first-line oesophageal cancer OK in Europe

https://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/

News/ News/ Oncology

Keytruda cuts risk of death by 31% in esophageal cancer trial

George Underwood Keytruda, MSD, oesophageal cancer 0 Comment

MSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma

Keytruda cuts risk of death by 31% in esophageal cancer trial

https://pharmaphorum.com/news/keytruda-cuts-risk-of-death-by-31-in-esophageal-cancer-trial/

Trending

oesophageal cancer

Login